Depressive Disorder and Anxiety Disorders Clinical Trial
Official title:
Emotional Processing in Healthy Male Volunteers Treated With GSK424887. A Single Centre, Randomised, Double-blind, Placebo-controlled Parallel Group Study
This will be a phase I, single centre, randomised, double blind, double-dummy, placebo controlled, parallel group single-dose study in healthy volunteers. The purpose of this study is to assess the effect of a single-dose administration of GSK424887, a potent, selective competitive antagonist of the human Neurokinin 1 (NK1) receptor and a potent inhibitor of the human serotonin transporter (SERT), at the maximum dosage of 100 mg versus placebo and versus citalopram (20 mg) on emotional processing in healthy male volunteers. Pharmacokinetics and safety following oral administration of GSK424887 will be also evaluated. An Emotional Test Battery (ETB) previously used to characterise the effects of antidepressants on positive and negative emotion processing in Healthy Volunteers and patients will be used. We hypothesise that GSK424887 will modulate emotional information processing acutely. We anticipate that these effects may be manifest at sub-effective levels of NK1 and SERT receptor occupancy, thus providing pharmacodynamic evidence of the synergistic interaction of the two mechanisms in humans.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00536679 -
Relative Bioavailability and Food Effect Study for GSK163090 in Healthy Male and Female Volunteers
|
Phase 1 | |
| Completed |
NCT00513565 -
A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00426608 -
To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.
|
Phase 1 | |
| Completed |
NCT01031186 -
First Time in Human Study
|
Phase 1 | |
| Completed |
NCT00435695 -
Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using PET Imaging In Healthy Males
|
Phase 1 | |
| Completed |
NCT00343707 -
PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of 2 Medications In Social Anxiety Patients
|
Phase 2 | |
| Completed |
NCT01059591 -
First Study in Humans With GSK424887
|
Phase 1 | |
| Completed |
NCT01059578 -
First Study in Humans With GSK206136
|
Phase 1 | |
| Completed |
NCT00703547 -
A First Time in Human Study of GSK586529 in Healthy Volunteers
|
Phase 1 |